等待开盘 09-14 09:30:00 美东时间
+0.013
+3.56%
U.S. stock futures rose, led by Nvidia (+4.7%) on strong Q2 revenue and guidance. Salesforce (+13%) and Okta (+19.2%) also gained, while HP fell 7.5%. Investors await BBY, WDAY, AFRM, GAP earnings and Jackson Hole symposium signals.
08-27 16:51
Nvidia +6.5% leads Tech; Mercer +60.7% on funding; SpaceX +1.2%; Tesla +0.6% denies shutdown; Walmart -0.5% on cautious consumers; Moderna +0.6% on cancer trial; KE Holdings +0.1%.
08-27 16:48
Mercer International Inc. ("Mercer" or the "Company") (NASDAQ:MERC), a global forest products company today announced that the Government of Canada, through Prairies Economic Development Canada ("PrairiesCan"), has committed C$20 million (approximately US$14 million) in financial support to its subs...
08-27 04:48
Mercer Intl (NASDAQ:MERC) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.63) by 79.37 percent. This is a 12.4 percent increase over losses of $(1.29) per share from the same period last year. The company reported quarterly sales of $460.278 million ...
08-07 05:48
今日重点评级关注:摩根大通:维持联合大陆航空"超配"评级,目标价从156美元升至203美元;摩根士丹利:维持联合大陆航空"超配"评级,目标价从185美元升至190美元
07-20 13:49
RBC Capital analyst Matthew McKellar maintains Mercer International (NASDAQ:MERC) with a Sector Perform and lowers the price target from $1 to $0.75.
07-17 23:30
美世国际(MERC)宣布,将其德国罗森塔尔纸浆厂原计划的两周维护停机时间延长至2026年9月整月,该欧洲核心生产基地将出现暂时性重大产出中断,目前公司正统筹各业...
07-01 05:58
Mercer International ( ($MERC) ) has shared an announcement. On June 30, 2026, ...
07-01 04:49
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Mercer International Inc.业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **盈利能力表现:** - 运营EBITDA为800万美元,环比增长2800万美元,主要得益于计划维护停机时间减少和"One Goal One Hundred"成本削减项目的执行 - 合并净亏损5200万美元(每股亏损0.78美元),包含2200万美元的非现金库存减值 - 纸浆业务板块EBITDA为700万美元,实木业务板块EBITDA为负600万美元 **收入表现:** - 大规模木材业务收入环比增长超过60%,生产增长超过20% -
06-02 12:08
今日重点评级关注:HC Wainwright & Co.:维持Caribou Biosciences"买入"评级,目标价从9美元升至11美元;康托·菲茨杰拉德:维持Artiva Biotherapeutics"超配"评级,目标价从10美元升至40美元
05-12 12:36